[go: up one dir, main page]

MX2015015434A - Corroles dirigidas para toxicidad tumoral y rm. - Google Patents

Corroles dirigidas para toxicidad tumoral y rm.

Info

Publication number
MX2015015434A
MX2015015434A MX2015015434A MX2015015434A MX2015015434A MX 2015015434 A MX2015015434 A MX 2015015434A MX 2015015434 A MX2015015434 A MX 2015015434A MX 2015015434 A MX2015015434 A MX 2015015434A MX 2015015434 A MX2015015434 A MX 2015015434A
Authority
MX
Mexico
Prior art keywords
subject
disclosed
mri
targeted corrole
corrole nanoparticle
Prior art date
Application number
MX2015015434A
Other languages
English (en)
Inventor
Lali K Medina-Kauwe
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of MX2015015434A publication Critical patent/MX2015015434A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan composiciones que comprenden nanopartículas corrole dirigidas; y un excipiente aceptable. También, se divulgan composiciones que comprenden nanopartículas corrole dirigidas; y un vehículo aceptable. Además, se divulgan en este documento los métodos de formación de imágenes de la afección de un sujeto, que comprenden proporcionar una composición que comprende una nanopartícula corrole dirigida; a administración de una cantidad efectiva de la nanopartícula corrole dirigida al sujeto; y la formación de imágenes de la afección el sujeto. Además, en lo sucesivo se divulgan métodos para tratar el cáncer en un sujeto, que comprenden una composición que comprende una nanopartícula corrole; y la administración de una dosis terapéuticamente eficaz de la nanopartícula corrole dirigida al sujeto.
MX2015015434A 2013-05-08 2014-05-08 Corroles dirigidas para toxicidad tumoral y rm. MX2015015434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361821106P 2013-05-08 2013-05-08
PCT/US2014/037234 WO2014182868A1 (en) 2013-05-08 2014-05-08 Targeting corroles for tumor toxicity and mri

Publications (1)

Publication Number Publication Date
MX2015015434A true MX2015015434A (es) 2016-03-15

Family

ID=51864925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015434A MX2015015434A (es) 2013-05-08 2014-05-08 Corroles dirigidas para toxicidad tumoral y rm.

Country Status (16)

Country Link
US (2) US9757386B2 (es)
EP (2) EP2993983B1 (es)
JP (1) JP6640715B2 (es)
KR (1) KR20160008523A (es)
CN (2) CN108451930A (es)
AU (2) AU2014262653B2 (es)
CA (1) CA2910030A1 (es)
DK (1) DK2993983T3 (es)
ES (1) ES2791043T3 (es)
IL (1) IL265935B (es)
MX (1) MX2015015434A (es)
PL (1) PL2993983T3 (es)
PT (1) PT2993983T (es)
RU (1) RU2674146C2 (es)
WO (1) WO2014182868A1 (es)
ZA (1) ZA201508092B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN104619839A (zh) 2012-08-03 2015-05-13 西塞医疗中心 药物递送蛋白质的增强运输的突变体的分离
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
RU2682335C2 (ru) 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
CA2943297A1 (en) 2014-04-04 2015-10-08 Cedars-Sinai Medical Center Targeting trastuzumab-resistant her2+ breast cancer with a her3-targeting nanoparticle
US20200345846A1 (en) * 2017-08-31 2020-11-05 Technion Research & Development Foundation Limited Corrole compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA129822A (en) 1910-08-24 1910-12-13 The John Bertram And Sons Company, Limited Motor controlling apparatus
CA140995A (en) 1912-03-05 1912-06-11 Davydd C. Hughes Type plate mechanism
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO2002094318A1 (en) 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
ATE472550T1 (de) * 2001-07-02 2010-07-15 Technion Res & Dev Foundation Verfahren zur herstellung selektiv substituierter corrole und neue substituierte corrole
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
EP2192899B1 (en) 2007-08-28 2014-10-01 Technion Research and Development Foundation, Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
ATE556708T1 (de) * 2008-01-31 2012-05-15 Technion Res & Dev Foundation Corrole für neuroprotektion und neuro-rescue
US8541568B2 (en) 2008-05-24 2013-09-24 Hai Yan Compositions and methods using siRNA molecules for treatment of gliomas
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN101704820A (zh) * 2009-09-24 2010-05-12 江苏大学 三(4-氯苯基)咔咯化合物及其合成方法
US20130065778A1 (en) 2010-01-26 2013-03-14 Yale University MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy
MX2014001823A (es) * 2011-08-15 2014-08-21 Technion Res & Dev Foundation Combinaciones de corroles y estatinas.
CN104619839A (zh) 2012-08-03 2015-05-13 西塞医疗中心 药物递送蛋白质的增强运输的突变体的分离
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
RU2682335C2 (ru) 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
CA2943297A1 (en) 2014-04-04 2015-10-08 Cedars-Sinai Medical Center Targeting trastuzumab-resistant her2+ breast cancer with a her3-targeting nanoparticle
CN109475636A (zh) 2016-05-27 2019-03-15 席德-西奈医疗中心 药物-递送纳米颗粒和耐药癌症的治疗

Also Published As

Publication number Publication date
RU2015152033A3 (es) 2018-04-25
ZA201508092B (en) 2017-02-22
HK1221870A1 (en) 2017-06-16
CN105307499B (zh) 2018-04-27
AU2018250401B2 (en) 2020-06-11
JP2016526021A (ja) 2016-09-01
PL2993983T3 (pl) 2020-09-07
US20140335025A1 (en) 2014-11-13
PT2993983T (pt) 2020-05-22
AU2018250401A1 (en) 2018-11-08
CN108451930A (zh) 2018-08-28
US20170281802A1 (en) 2017-10-05
IL265935A (en) 2019-05-30
RU2674146C2 (ru) 2018-12-07
EP2993983B1 (en) 2020-03-25
JP6640715B2 (ja) 2020-02-05
AU2014262653A1 (en) 2015-11-12
DK2993983T3 (da) 2020-05-18
EP2993983A1 (en) 2016-03-16
RU2015152033A (ru) 2017-06-16
EP2993983A4 (en) 2017-01-11
US10709801B2 (en) 2020-07-14
CN105307499A (zh) 2016-02-03
ES2791043T3 (es) 2020-10-30
KR20160008523A (ko) 2016-01-22
WO2014182868A1 (en) 2014-11-13
IL265935B (en) 2020-06-30
US9757386B2 (en) 2017-09-12
AU2014262653B2 (en) 2018-07-26
CA2910030A1 (en) 2014-11-13
EP3730155A1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
NZ752526A (en) Pyrrolobenzodiazepine conjugates
PH12016502066A1 (en) Methods of treating bladder cancer
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX2017007321A (es) Terapias de combinacion.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX375442B (es) Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
NZ700759A (en) Combination therapy for treating cancer
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
NZ705910A (en) Pyrrolobenzodiazepines and conjugates thereof
MY185650A (en) Cancer treatment with combinantion of plinabulin and taxane
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
PH12015502536B1 (en) Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
HK1251488A1 (zh) 作为放射致敏剂以及mri和/或x光造影剂的结合纳米粒子的抗核仁素剂
MY189663A (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
WO2013052158A3 (en) Targeted nanovectors and their use for treatment of brain tumors
MX2021001832A (es) Conjugados para su uso en metodos de tratamiento del cancer.
WO2015148971A3 (en) Method for detecting or treating triple negative breast cancer
MX2015004703A (es) Composiciones cancerigenas inyectables.